By Sophie Lindqvist

A new Physician's Weekly feature reframes how clinicians should approach psoriasis. The review, titled "Personalizing Psoriasis Treatment: Considerations for Comprehensive Management," pushes the field past lesion-only thinking.

It argues for a wider lens.

Dermatology has spent two decades optimizing for clearance. The new editorial frame widens to the patient sitting in front of the prescriber, not just the plaques on exam. The shift is small in language. It is large in practice.

What does this change for the prescribing dermatologist? It changes the structure of the first ten minutes of the consult.

What the title tells us

The review's central premise sits in three words: comprehensive management. That phrase has done a lot of work in dermatology literature over the past five years. It signals a move away from monotherapy score-chasing and toward a plan that wraps in comorbidity screening, lifestyle factors, mental-health load, and therapy sequencing. The Physician's Weekly feature joins a steady drumbeat of similar framing in the major dermatology journals.

Why the framing matters

A patient with PASI 12, a sedentary job, a history of depression, and untreated hypertension is not the same clinical challenge as a patient with PASI 12 and no comorbidities. The first patient needs cardiovascular risk workup, mental-health screening, and a frank conversation about weight and alcohol before any prescription lands. The second can move faster on the classic severity ladder.

The point is not new. The bundling is.

How personalization lands in practice

The review's framework, drawn from the title's framing, walks through the practical moves a comprehensive plan should cover:

• Screen first, treat second. Comorbidity screening sets the clinical floor.
• Match the molecule to the patient profile, not the plaque count alone.
• Build reassessment intervals around real-life endpoints, not just PASI 50 or PASI 90.
• Plan for therapy switches before the first prescription is written.
• Loop in primary care, rheumatology, and mental health early, not at crisis.

Most clinics do pieces of this. Few do all of it consistently. The review's value is in the bundling.

Why the audience matters

Physician's Weekly sits in the continuing-medical-education corner of the medical press. Its features reach a wide audience of internists, family physicians, and specialists. A feature-length treatment of personalization signals where the broader medical conversation is moving. Psoriasis care is no longer just a dermatology story. It is a primary-care story with dermatology at the steering wheel.

That has reimbursement implications. Staffing implications. Referral-pattern implications. The review is short on those specifics. The implications are not.

What practitioners should take away

Three things.

First, build the consult around the whole patient, not the plaque. Standardize the comorbidity screen. Make it part of every first visit.

Second, choose therapy with the patient profile in view. The biologic class that suits a 28-year-old woman planning pregnancy is not the biologic class that suits a 60-year-old man with a history of recurrent infections.

Third, document the comprehensive plan. Payers, increasingly, want to see the reasoning. A clear framework gives clinicians a defensible structure.

What comes next

Expect more of this framing to land in CME programming, payer policy, and electronic health-record templates over the next 12 months. The plaque score is not going away. It is just becoming one input among many.